Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zishen Yangyin Qingre Fang is a Traditional Chinese Medicine (TCM) herbal prescription developed by the Yunnan Provincial Hospital of Traditional Chinese Medicine for the treatment of systemic lupus erythematosus (SLE). The formula is specifically indicated for patients exhibiting the 'yin deficiency and internal heat' TCM pattern, a common clinical presentation in SLE. Its therapeutic objectives are to nourish the kidney, replenish yin, and clear pathogenic internal heat to stabilize the immune system. In clinical trial settings (e.g., ChiCTR2300070732), it is evaluated as an adjunctive therapy to standard Western medicine, such as corticosteroids and immunosuppressants, to improve clinical outcomes, reduce disease activity, and potentially minimize the side effects of conventional therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zishen yangyin qingre fang.